Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

BACKGROUND & AIMS Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients who relapse or do not respond to therapy. METHODS This prospective, international, multicenter, open-label study evaluated efficacy and safety of peginterferon alfa-2b (1.5 microg/kg/wk) plus weight-based ribavirin (800-1400 mg/day) in 2333 chronic HCV-infected patients with significant fibrosis/cirrhosis whose previous interferon alfa/ribavirin therapy failed. Patients with undetectable HCV-RNA at treatment week (TW) 12 received 48 weeks of therapy; patients with detectable HCV-RNA at TW12 could enter maintenance studies at TW18; 188 patients with low/detectable HCV-RNA at TW12 continued therapy at the investigator's request. RESULTS Overall, 22% of the patients attained SVR (56% with undetectable HCV-RNA and 12% with low/detectable HCV-RNA at TW12). SVR was better in relapsers (38%) than nonresponders (14%), regardless of previous treatment, and in patients previously treated with interferon-alfa/ribavirin (25%) than peginterferon alfa-ribavirin (17%). Predictors of response in patients with undetectable HCV-RNA at TW12 were genotype (2/3 vs 1, respectively; odds ratio [OR] 2.4; P < .0001), fibrosis score (F2 vs F4; OR, 2.2; F3 vs F4; OR, 1.7; P < .0001), and baseline viral load (< or =600,000 vs >600,000 IU/mL; OR, 1.4; P = .0223). These factors plus previous treatment and response were overall predictors of SVR. Safety was similar among fibrosis groups. CONCLUSIONS Peginterferon alfa-2b plus weight-based ribavirin is effective and safe in patients who failed interferon alfa/ribavirin therapy. Genotype, baseline viral load, and fibrosis stage were predictors of response.

[1]  A. Andriulli,et al.  Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial , 2007, Hepatology.

[2]  Brian L. Pearlman,et al.  Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders , 2007, Hepatology.

[3]  M. Manns,et al.  Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis , 2007, Annals of Internal Medicine.

[4]  P. Marcellin,et al.  Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? , 2007, Journal of hepatology.

[5]  P. Kwo,et al.  Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial , 2007, Hepatology.

[6]  D. Häussinger,et al.  Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[7]  T. Asselah,et al.  High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. , 2007, Journal of hepatology.

[8]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[9]  R. Andrade,et al.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.

[10]  M. Sherman,et al.  Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy , 2006, Gut.

[11]  L. Messerini,et al.  Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. , 2006, Gastroenterology.

[12]  T. Berg,et al.  Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.

[13]  M. Manns,et al.  Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. , 2006, Journal of hepatology.

[14]  E. Parise,et al.  Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. , 2006, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[15]  E. Bini,et al.  A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.

[16]  T. Ashikaga,et al.  Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. , 2005, Journal of hepatology.

[17]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[18]  F. Nevens,et al.  Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378] , 2003, BMC gastroenterology.

[19]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[20]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[21]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[22]  Z. Goodman,et al.  Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? , 2000, Hepatology.

[23]  M. Vidaud,et al.  Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. , 1999, Gastroenterology.

[24]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[25]  D. Harnois Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon , 2009 .

[26]  R. Levine,et al.  3 COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL , 2008 .

[27]  S. Artioli,et al.  Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[28]  M. Shiffman Management of patients with chronic hepatitis C virus infection and previous nonresponse. , 2004, Reviews in gastroenterological disorders.